Currently, adjuvant pembrolizumab (anti-PD1), nivolumab (anti-PD1), or combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) are recommended for resected stage III melanoma (dependant on BRAF status) [26, 27]. This evidence concerns the gene MAP2K7 and melanoma.